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Abstract
Background: Placental malaria (PM) is associated with prenatal malaise, but many PM+ infants are born without
symptoms. As malaria has powerful immunomodulatory effects, we tested the hypothesis that PM predicts reduced
T-cell responses to vaccine challenge.
Methods: We recruited healthy PM+ and PM- infants at birth. At six and 12 months, we stimulated PBMCs with
tuberculin purified protein derivative (PPD) and compared expression of CD154, IL-2 and IFNg by CD4 T-cells to a
negative control using flow cytometry.
We measured the length, weight and head circumference at birth and 12 months.
Results: IL-2 and CD154 expression were low in both groups at both timepoints, without discernable differences.
Expression of IFNg was similarly low at 6 months but by 12 months, the median response was higher in PM- than
PM + infants (p = 0.026). The PM+ infants also had a lower weight (p = 0.032) and head circumference (p = 0.041)
at 12 months, indicating lower growth rates.
At birth, the size and weight of the PM+ and PM- infants were equivalent. By 12 months, the PM+ infants had a
lower weight and head circumference than the PM- infants.
Conclusions: Placental malaria was associated with reduced immune responses 12 months after immune
challenge in infants apparently healthy at birth.
Background
Plasmodium falciparum malaria is endemic in much of
Sub-Saharan Africa and commonly infects the placentas
of pregnant women. The overt consequences of placen-
tal malaria (PM) include high risk of premature birth
and low birth weight [1,2], increased neonatal mortality
[3] and infant anaemia [4]. Exposure to PM has been
associated with an increased risk for malaria during the
first years of life [5].
Placental malaria has been associated with poor cyto-
kine production by T-cells [6,7] and induced tolerance
to Plasmodium antigens [8], which may be associated
with the induction of regulatory T-cells in PM-exposed
infants [9-11]. These findings are consistent with earlier
results that showed that malaria in children led to
reduced antibody responses to vaccination with bacterial
polysaccharide, glycoconjugate and protein antigens
[12-16], and also that prenatal exposure to malaria is
associated with relatively low cytokine responses to P.
falciparum antigens for at least the first three years of
life [8].
The effect of malaria may be partly responsible for the
observation that in regions of Sub-Saharan Africa where
P. falciparum malaria is endemic, several vaccines used
for routine childhood immunisation are frequently less
effective than in high income countries, which was the
subject of a recent review [17].
One of the best documented examples is that of the
Bacille Calmette-Guérin (BCG) vaccine for tuberculosis,
which has demonstrated good protection in most trials
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protection in trials carried out in low income tropical
countries [18]. Mechanisms of protection against tuber-
culosis have not been defined, but defects in IFNg sig-
nalling are strongly predictive of disease so it is likely
that the T-cell response plays an important part in pro-
tection [19-21].
A possible explanation for the low levels of protection
afforded by BCG in sub-Saharan Africa is offered by the
finding that BCG does not induce the same level of T-
cell IFNg production in Malawian children as it does in
British children [22,23].
We hypothesised that the immunomodulatory effects
of P. falciparum infection of the placenta extend to
immune challenges encountered during the early post-
natal period. We conducted a preliminary study using
an existing dataset derived from the Sukuta Birth
Cohort in The Gambia, which was collected in order to
study the development of CD4 T-cell responses to cyto-
megalovirus (CMV) in early life [24,25], to establish
whether there was an association between PM and CD4
T-cell responses to the BCG vaccination.
Methods
Cohort characteristics
Healthy infants were recruited from the maternity ward
of Sukuta Health Centre, following written informed
consent from both parents. Sukuta Health Centre serves
a low income, peri-urban community in The Gambia.
Malaria transmission rates are at their highest during
and immediately after the wet season, giving rise to a
distinct malaria season from August to December [25].
Recruitment took place from January to August, 2002.
Infants were recruited at birth, and the cohort was
restricted to healthy infants by excluding infants with a
birthweight below 2.0 kg, infants born from pregnancies
with complications that required hospital admission and
infants with congenital abnormalities. Twins were also
excluded.
From the existing dataset, we identified a PM+ group
consisting of all infants exposed to placental malaria
whose response to PPD had been measured at either six
(23-30 weeks) or 12 months (46-58 weeks) or both. We
then identified a PM- group of all infants whose
r e s p o n s et oP P Dh a db e e nm e a s u r e da tt h es a m ea g e s ,
and whose placentas showed no signs of malarial
infection.
At birth, the APGAR score at 5 min was recorded.
Babies were weighed, the length was measured with a
measuring board, and a tape measure was used to mea-
sure the head and mid-upper arm circumferences. The
weight, length and head circumference were measured
again at 12 months.
All infants were immunised intradermally with BCG
within 24 h of birth according to the Gambian expanded
program of immunisation.
Mothers were requested to bring infants to the clinic
if they became ill at any point during follow up, where
treatment was provided and details of the illnesses
recorded.
The study was approved by the Gambia Government/
MRC Laboratories Joint Ethics Committee.
Intracytoplasmic cytokine staining
The PBMCs were isolated by density gradient centrifuga-
tion using lymphoprep (Axis-Shield POC AS, Oslo, Nor-
way) and resuspended at 2 × 10
6 cells ml
-1 in R10F (90%
v/v RPMI-1640 containing 100 U ml
-1 penicillin plus 100
μgm l
-1 streptomycin, 10% v/v fetal bovine serum) and
treated with either 10 μgm l
-1 of the RT49 preparation of
tuberculin purified protein derivative (PPD) (Statens
Serum Institut, Copenhagen, Denmark), 10 μgm l
-1 lysed
CMV-infected human dermal fibroblast cells (Virusys,
Taneytown, MD, USA), or 10 μgm l
-1 normal human der-
mal fibroblast lysate (NHDF) (Virusys) [26] as a negative
control, as required by the CMV study [24]. After 2 h at
37°C in a 5% carbon dioxide atmosphere, cytokine secre-
tion was inhibited with 10 μgm l
-1 brefeldin A (Sigma,
Natick, MA, USA) and the PBMCs were incubated for a
further 16 h. The PBMCs were concentrated by centrifu-
gation, permeabilised using FACSperm II solution (BD
Biosciences, Franklin Lakes, NJ, USA), and stained with
PerCP-conjugated anti-CD4 antibodies, FITC-conjugated
anti-IFN-g antibodies, PE-conjugated anti-CD154 antibo-
dies, and APC-conjugated anti-IL-2 antibodies. All anti-
bodies were obtained from BD. The stained cells were
stored in 2% v/v formalin in phosphate-buffered saline at
4°C and as many cells as possible were acquired on a
four-color FACScalibur (BD), and analyzed using FCS
Express (De Novo Software, Los Angeles, CA, USA).
CD4 T-cells were identified as having high levels of stain-
ing for CD4 (median number of CD4 T-cells 28,506, IQR
9,899-61,453). Cells expressing markers of interest were
identified by setting gates on negative control cells to
identify non-responding cells, and applying the same
gates to the PPD-stimulated cells (Figure 1). The PPD
and CMV-specific responses were defined as the percen-
tage of CD4 T-cells expressing each marker among the
PPD-treated cells after subtraction of the percentage of
CD4 T-cells expressing each marker among the negative
control cells.
Diagnosis of placental malaria
PM was diagnosed from a 1 cm × 2 cm × 2 cm biopsy
of the placenta that was stained with haematoxylin and
eosin and examined under a light microscope by two
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tion was found, it was classified as past, acute or chronic
infection [27].
Statistical analysis
Data on PPD responses were available from 24 infants at
6 months, of whom five were PM+ at birth. Data were
available from 35 infants at 12 months, of whom seven
were PM+ at birth. The low numbers made it impossi-
ble to analyse acute, chronic and past infection sepa-
rately, so infants with any presentation of PM were
classified as PM+ and compared with PM- infants.
Mann-Whitney U tests were used to compare mea-
surements of weight, size, APGAR score and CD4
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Figure 1 Gating of CD4 T-cells expressing IFNg, IL-2 and CD154. Following selection of lymphocytes by forward and side scatter
characteristics and CD4 T-cells by gating on high expression of CD4, quadrant gates were set on a/the negative control sample and then
applied to b/the PPD-stimulated sample. Sample selected as representative as it has the median CD154 response among PM- infants at 12
months.
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with Stata 9.1 (StataCorp LP, College Station, TX, USA)
and MINITAB 14 (Minitab inc, State College, PA, USA).
Results
Clinical characteristics
The size, weight and APGAR scores of PM+ and PM-
infants were equivalent at birth (Table 1). By 12 months
of age, the median weight and head circumference of
the PM- infants were greater than those of the PM+
infants, although there was no discernable difference in
length (Table 2).
Of the five PM+ infants sampled at six months, two
were diagnosed with acute infection, one with chronic
infection and two with past infection. Of the seven PM+
infants sampled at 12 months, three had acute infection,
one had chronic infection and three had past infection.
During the follow-up period, malaria infections were
diagnosed in three of the 28 PM- infants and none of
the seven PM+ infants, which was not a significant
difference.
Less CD4 T-cells produced IFNg in response to PPD
following exposure to placental malaria
At 6 months, very few PPD-specific IFNg-producing
CD4 T-cells were found in any of the infants, and there
were no significant differences in responses between PM
+ (median 0.002%, IQR -0.008; 0.007%) and PM- (med-
ian 0.005%, IQR 0.001; 0.011%) groups. By 12 months of
age, most of the PM- infants had at least some PPD-
specific response, and the proportion of PPD-specific
IFNg-producing CD4 T-cells was significantly higher in
PM- (median 0.007%, IQR 0.002; 0.037) than PM+
infants (median 0.000%, IQR -0.002; 0.002%) (p =0 . 0 2 6 )
(Figure 2).
Few CD4 T-cells responded to PPD by producing IL-2 or
CD154
The median PPD-specific IL-2 and CD154 responses of
both PM+ and PM- infants were negative at 6 months,
indicating that percentages of responding PPD-treated
cells were below negative control levels. By 12 months
the median PPD-specific response of PM- infants was
positive, albeit very low, for IL-2 (median 0.002%, IQR
-0.002; 0.009) and CD154 (median 0.003%, IQR -0.026;
0.009). Median responses of PM+ infants remained
negative and very close to zero, but there was no signifi-
cant difference between PM+ and PM- groups.
No association between PM and responses to CMV
As the majority of the infants were infected with CMV,
we also compared the CD4 T-cell responses to CMV
lysate between PM- and PM+ infants. The numbers
available were 5 PM+ and 20 PM- at 6 months, and 5
PM+ and 24 PM- at 12 months.
We found no significant differences in the percentages
of CD4 T-cells expressing IFNg, IL-2 or CD154 between
PM+ and PM- infants, either at six or 12 months of age
(data not shown).
Discussion
Our principal finding is that placental malaria predicted
a relatively weak IFNg response to PPD a year after
birth, which was also a year after the administration of
the BCG vaccine. No difference was detectable at 6
months, probably because of the low response in both
groups.
By contrast, we did not find an association between
PM and responses to CMV. There are distinct differ-
ences in the presentation of BCG and CMV, as the BCG
vaccine is administered within 24 h of birth and is pre-
sent for a limited period of time. Gambian infants are
usually infected with CMV several weeks after birth
[28], after which it establishes a persistent infection so
that the host is exposed to CMV antigens for the rest of
their life [29]. The contrast between the associations
with BCG and CMV suggests two mutually compatible
explanations. The first is that the influence of PM on
the response to BCG is stronger because the exposure
to BCG occurred chronologically closer to the exposure
to the exposure to placental malaria. The other is that
the persistently high antigen exposure in CMV-infected
infants drove the immune response to overcome any
deleterious influence of PM.
The lack of effect on responses to CMV contrasts with
earlier findings that malaria episodes are associated with
Table 1 Size, weight and APGAR scores of PM+ and PM- infants at birth
PM+ (n = 7) PM- (n = 28)
Parameter Median IQR Median IQR
APGAR score 9 9-10 9 9-10
Birthweight (kg) 2.95 2.73-3.11 2.93 2.70-3.40
Length (cm) 49 48-51 49 48-50
Head circumference (cm) 34 33-34 34 33-35
Mid-upper arm circumference (cm) 10.6 9.7-11.0 9.8 9.6-10.5
None of the differences were significant
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Barr virus (EBV), and also with higher EBV viral loads
[30-32], implying poor immune control of viral replica-
tion. However, our study differs substantially from the
studies that generated these findings as apart from the
fact that the natural histories of CMV and EBV infection
are very different, the children in our study were
younger than most of those in the previous studies.
Further, the previous studies were on children who
either had a recent malaria episode or were frequently
infected, while the infants in our cohort were exposed
to PM and very few developed malaria in the subse-
quent year, implying little or no exposure to P.
falciparum.
We have previously reported that in BCG-vaccinated
infants below 12 months, few CD4 T-cells produce IFNg
in response to PPD [33], so it is likely that differences
associated with PM were simply undetectable until the
CD4 T-cells of the infants were producing enough IFNg
for a difference to be apparent.
The numbers were too small to analyse for the effects
of acute, chronic and past PM. However, the relative
proportions of the three types were similar in the infants
sampled at six and 12 months, making it unlikely that
the appearance of a difference at 12 months was due to
a difference in the type of PM among the PM+ infants.
The sizes and weights of infants at birth in the PM+
and PM- groups were comparable, so we could exclude
the confounding effects of premature birth and low
birth weight which are well described for PM [1,2]. The
exclusion criterion of low birthweight also ruled out the
effect of prenatal undernutrition, which is associated
with poor immune development [34,35] and while we
have previously found an association between PM and
congenital cytomegalovirus infection [36], we found no
evidence that congenital cytomegalovirus modulated the
responses of CD4 T-cells to PPD [24] in a much larger
and more powerful study.
Testing for HIV was not carried out, but a survey car-
ried out in the nearby town of Serrekunda from 2000 to
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Figure 2 Percentages of CD4 T-cells that expressed IFNg at a/6 months and b/12 months compared by placental malaria (PM) status
of the infant. Bars indicate medians. Statistical comparisons by Mann-Whitney U test.
Table 2 Weight, length and head circumference measured at 12 months of age
PM+ (n = 7) PM- (n = 28) p
Parameter Median IQR Median IQR
Weight (kg) 8 7.30-8.46 9.14 8.05-10.18 0.032
Length (cm) 72.8 71.0-74.4 73.5 72.5-75.4 NS
Head circumference (cm) 44.5 43.5-45.0 45.5 44.6-46.38 0.041
Comparisons by Mann-Whitney U test. NS indicates non-significant
Walther et al. BMC Infectious Diseases 2012, 12:6
http://www.biomedcentral.com/1471-2334/12/6
Page 5 of 72001 found a prevalence of 1.0% among pregnant
women [37], and a recent screen of women in Sukuta
confirmed the rates to be < 1% (unpublished), thus HIV
was unlikely to be a serious confounder.
Helminth infection has been shown to modulate
immune responses to mycobacterial antigens in BCG-
vaccinated children [38-40], but we found that intestinal
helminth infections are not endemic in infants in the
Sukuta area after a screen of fecal samples collected at
12 months of age (unpublished). However, the possibi-
lity has been raised that helminth infection during preg-
nancy may reduce the IFNg response to PPD [41],
which we cannot eliminate as we did not screen the
mothers for intestinal infections.
By 12 months of age, the PM+ infants were slightly
smaller than the PM- infants. As there were no differ-
ences at birth, the difference at 12 months implies that
PM was associated with reduced growth, which concurs
with our findings from the entire cohort from which
infants were selected for the analysis presented here
[25]. Similarly, the differences in IFNg response emerged
between 6 and 12 months, suggesting that PM was pre-
dictive of deleterious effects that remained present 12
months after birth.
Although no correlate of protection to tuberculosis
has been identified, the ability to generate IFNg-produ-
cing T-cells has been shown to be important, as defects
in IFNg signalling lead to a high susceptibility to tuber-
culosis disease [19-21]. Whi l ei ti sp o s s i b l et h a tt h e
reduced number of IFNg-producing cells indicated a
shift in response profile, rather than an overall loss of
T-cell response, it is still likely that a reduced number
of IFNg-producing CD4 T-cells represents a reduced
level of protection.
While we detected an association between PM and
reduced immune response to BCG vaccination at
birth, the scope of the study did not extend to estab-
lishing whether there was a direct causal link.
Although PM makes infants more susceptible to sub-
clinical P. falciparum infection and episodes of
malaria [5,8,42], it is unlikely that the lower responses
of PM+ infants were due to the immunosuppressive
effect of repeated malaria episodes [43,44] as we did
not find a higher rate of malarial disease in PM +
infants. While we could not exclude all possible con-
founders, no effect that we were able to measure
showed any association with reduced responses other
than exposure to PM.
Conclusions
The fact that an association between PM and reduced
immune responses was detectable with such low num-
bers suggests a strong association between PM and
reduced CD4 T-cell response. As subclinical PM is
common in Sub-Saharan Africa, a study on a large
enough scale to confirm our findings and investigate the
mechanism may yield results that are important for
infant health in the region.
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